CapsoVision opened higher at $6.30, compared with its previous close of $6.27. In the last trading session, the stock traded between $6.12 and $6.40. It showed an upward intraday trend.
An investment of $100 made 2 years ago in CapsoVision is now worth
$ 180.60
Giving a profit of
$ 80.60 (80.60%)
Note: Past profits do not guarantee future returns.
Rating from 1 Analysts
Today's Change
+$0.05 (+0.81%)
Day High
$6.40
Day Low
$6.12
Day Open
$6.30
Prev Close
$6.27
Volume
67,669
1W Return
-8.06%
1M Return
-6.63%
3M Return
-3.94%
6M Return
-13.05%
1Y Return
16.09%
Market Cap ($ Mn)
336
PE Ratio
-
PB Ratio
22.61
PEG Ratio
-
ROE
-
ROCE
-197.21%
EPS (TTM)
-
1 Week
-8.06%
1 Month
-6.63%
3 Months
-3.94%
6 Months
-13.05%
9 Months
30.87%
CapsoVision raises $17.83M via discounted share sale to insiders
CapsoVision offers 3,163,444 shares at $5.69 each. Net proceeds expected at $17,834,500 after expenses. Buyers include related parties Star One Global Capital and Eliyahou Harari. Price reflects a 5% discount to last reported Nasdaq sale price.
1mo agoCapsoVision files prospectus for up to $250M equity offering
CapsoVision, Inc. filed a prospectus for a maximum $250 million offering of common stock, preferred stock, warrants, rights, and units. The company may sell these securities in any combination, with specific terms and prices to be determined at the time of each offering. Detailed information will be provided in subsequent supplements to the prospectus.
3mo agoCapsoVision Q2 Results: Revenue rises 10% to $3.6 million
CapsoVision reported Q2 2026 revenue of $3.6 million, up 10% YoY, driven by a 13% increase in capsule shipments to 8,845 units. Gross margin fell to 51% from 55% due to pricing pressure and tariffs, while operating expenses rose to $9.5 million. The company launched AI Highlights internationally and expects U.S. FDA clearance by Q3 2026.
3mo agoCapsoVision enters $100M ATM sales agreement with Cantor Fitzgerald
CapsoVision disclosed an SEC filing regarding a new sales agreement with Cantor Fitzgerald. The deal enables an at-the-market offering of shares worth up to $100 million. This provides the company with a flexible channel to raise capital as needed.
3mo agoCapsoVision launches AI Highlights in EU for CapsoCam Plus
CapsoVision Inc (NASDAQ: CV) launched AI Highlights for CapsoCam Plus in the EU on Aug. 03, 2026. The tool identifies clinically relevant findings in small bowel studies via CapsoView and CapsoCloud. It is MDR-compliant in Europe but lacks FDA clearance for the US.
3mo agoCapsoVision Q2 Results: Second quarter financials due Aug 13
CapsoVision Inc will release its second quarter 2026 financial results on August 13, 2026, after market close. A conference call and webcast will follow at 1:30 pm PT to discuss the results and corporate updates. The company continues to develop its AI-enabled capsule endoscopy solutions for gastrointestinal disease detection.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $109.29 | -1.06% | $1,89,283.94M | 36.28 | |
| $449.53 | -0.11% | $1,55,826.88M | 42.73 | |
| $101.61 | +0.02% | $1,29,976.46M | 24.46 | |
| $318.79 | -1.70% | $1,21,360.48M | 34.27 | |
| $45.13 | +0.96% | $65,414.72M | 18.96 | |
| $105.81 | +1.73% | $60,840.75M | 53.70 | |
| $214.52 | +0.90% | $58,432.46M | 44.07 | |
| $82.60 | -1.26% | $37,346.60M | 16.49 | |
| $42.16 | +3.06% | $37,044.18M | 89.05 | |
| $72.46 | -2.16% | $35,027.16M | 54.55 | |
| $237.20 | +1.61% | $33,458.08M | 23.04 | |
| $80.35 | +0.53% | $29,964.75M | 36.04 |
An investment of $100 made 2 years ago in CapsoVision is now worth
$ 180.60
Giving a profit of
$ 80.60 (80.60%)
Note: Past profits do not guarantee future returns.
